Reuters logo
7 months ago
BRIEF-Lipocine Inc plans to initiate a dosing flexibility study
January 5, 2017 / 1:44 PM / 7 months ago

BRIEF-Lipocine Inc plans to initiate a dosing flexibility study

Jan 5 (Reuters) - Lipocine Inc :

* Lipocine inc- plans to initiate a dosing flexibility study in addition to its previously announced dosing validation study for lpcn 1021

* Lipocine - expects resubmission of lpcn 1021 new drug application to u.s. Food and drug administration to contain data from both dv study and df study

* Lipocine inc- expects first patient of df study to be enrolled in q1 of 2017 with top-line results projected in q2 of 2017

* Lipocine inc- remain on track with dv study and continue to expect top-line results from dv study in q2 of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below